Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q7Z7L1
UPID:
SLN11_HUMAN
Alternative names:
-
Alternative UPACC:
Q7Z7L1; E1P643; Q8N3S8; Q8N762; Q8TEE0
Background:
Schlafen family member 11 (SLFN11) is a pivotal protein that inhibits DNA replication, promoting cell death in response to DNA damage. It serves as a guardian of the genome, ensuring cellular integrity by eliminating cells with defective replication mechanisms. SLFN11 blocks stressed replication forks, leading to cell death. Additionally, it functions as an antiviral protein against retroviruses like HIV-1 by inhibiting viral protein synthesis through a unique mechanism involving tRNA binding.
Therapeutic significance:
Understanding the role of Schlafen family member 11 could open doors to potential therapeutic strategies. Its unique mechanism of action in both DNA damage response and antiviral defense positions SLFN11 as a promising target for developing treatments against cancer and viral infections.